Keymed Biosciences Inc. (HKG:2162)
Hong Kong · Delayed Price · Currency is HKD 54.55
-1.20 (-2.15%)
At close: Feb 13, 2026
Keymed Biosciences Market Cap
Keymed Biosciences has a market cap or net worth of 16.07 billion as of February 13, 2026. Its market cap has increased by 96.33% in one year.
Market Cap
16.07B
Enterprise Value
13.96B
Revenue
955.73M
Ranking
n/a
PE Ratio
n/a
Stock Price
54.55
Market Cap Chart
Since July 8, 2021, Keymed Biosciences's market cap has decreased from 18.43B to 16.07B, a decrease of -12.79%. That is a compound annual growth rate of -2.93%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 13, 2026 | 16.07B | 2.06% |
| Dec 31, 2025 | 15.75B | 84.90% |
| Dec 31, 2024 | 8.52B | -37.32% |
| Dec 29, 2023 | 13.59B | -4.15% |
| Dec 30, 2022 | 14.17B | 46.87% |
| Dec 31, 2021 | 9.65B | -47.63% |
| Jul 8, 2021 | 18.43B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Genscript Biotech | 26.33B |
| InnoCare Pharma | 25.42B |
| PegBio | 24.66B |
| Zai Lab | 17.55B |
| Ascentage Pharma Group International | 17.48B |
| Ascletis Pharma | 17.42B |
| Everest Medicines | 13.85B |
| Guangzhou Innogen Pharmaceutical Group | 12.61B |